

Except for US patent documents, a copy of each listed reference is enclosed or submitted herewith.

Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

This information disclosure statement is being filed **after** the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this information disclosure statement is a Request for Continued Examination. Therefore, no additional fee is due. Please charge any additional fees, should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicant(s) respectfully request(s) that any references or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: May 26, 2010

/ Teresa Chen, Reg. No. 55,352/_____
Teresa Chen, Reg. No. 55,352
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE